Camp4 Therapeutics (CAMP) AGM 2026 summary

Opening remarks and agenda

• Meeting held in an all-virtual format, ensuring equal participation rights for all stockholders.

• Introductions included board members, executive officers, independent auditor, and inspector of election.

• Stockholders informed about the process for submitting questions and the meeting's focus on business-related matters.

Board and executive committee updates

• Board members and executive officers present included the CEO, CFO, VP of Corporate and Legal Affairs, and several directors.

Overview of voting outcomes

• Quorum established with approximately 77% of shares represented.

• Election of three Class II directors for terms ending at the 2029 annual meeting was approved.

• Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026, was approved.

• Amendment to the 2024 Equity Incentive Plan was approved.

• Final vote results to be filed in Form 8-K within four business days.